LUMICKS funding news – Amsterdam -based LUMICKS Secures €20Million in Venture Debt Funding

LUMICKS’ Cell Avidity technology is transforming the discovery process in cancer immunotherapy by addressing a critical challenge: the lack of tools to directly measure the binding interaction of immune cells, such as CAR-T cells, with cancer cells.

Read also - Harmonic Security funding news – London-based Harmonic Security Raises $17.5Million in Series A Round Funding

This limitation creates uncertainties in the preclinical funnel and slows therapy development. By providing high-throughput measurement of such interactions, LUMICKS’ empowers researchers to optimize therapies faster and with greater accuracy, with the goal of improving success rates in clinical trials.

EIB vice president Robert de Groot said, “The Netherlands is home to a vibrant Life Sciences industry and the EIB has been proudly supporting this sector to ensure it continues to lead in medical innovation and transformative healthcare solutions, The new financing to LUMICKS is a testament of this. With the backing of InvestEU, the EIB can provide LUMICKS with stable long-term funding matching the highly innovative profile of the Company and tailored to its current needs for continued growth, market expansion, and development of its technologies.”

LUMICKS CEO Hugo de Wit said, “This investment from the EIB enables us to accelerate our R&D timeline, ensuring we continue innovating to deliver a long-lasting impact in the immunotherapy space” “By providing deeper insights into cellular interactions, our instruments empower researchers to make faster, better-informed decisions, with the goal of improving success rates in clinical trials and accelerating the development of effective therapies.”

The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals. Over the last ten years, the EIB has made available more than €27 billion in financing for Dutch projects in various sectors, including research & development, transport, drinking water, healthcare and SMEs.

The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investment for EU policy priorities, such as the European Green Deal and the digital transition. InvestEU brings together under one roof the multitude of EU financial instruments previously available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible.

The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is deployed through implementing partners who will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.

About LUMICKS

LUMICKS, founded in 2014, employs 170 people globally and has a proven track record of developing and commercializing cutting-edge life science tools. Widely adopted by top universities and research institutions worldwide, LUMICKS’ technologies have contributed to numerous publications in top journals across fields such as oncology and immunotherapy.